Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven M. Horwitz, June Weon Cheong, Owen A. O’Connor et al.|The Lancet|2018Cited by 733
The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study.Ora Paltiel, Dina Ben Yehuda, Tal Schmit et al.|PubMed|2000Cited by 65
The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphomaOra Paltiel, Dina Ben Yehuda, Bella Adler et al.|Cancer|2000Cited by 62
Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 StudyEldad J. Dann, Ora Paltiel, Osnat Bairey et al.|Blood|2014Cited by 4
Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.Eldad J. Dann, Ora Paltiel, Osnat Bairey et al.|Blood|2010Cited by 4